RA0801

antibody from Oursmab

Targeting: TREM2 TREM-2, Trem2a, Trem2b, Trem2c

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0801

Provider

Oursmab

Product name

Iluzanebart (Biosimilar Reference Antibody) (TREM2)

Antibody type

Monoclonal

Description

Iluzanebart is an investigational, fully human monoclonal immunoglobulin G1 (IgG1) antibody developed as a therapeutic agonist for human Triggering Receptor Expressed on Myeloid cells 2 (TREM2). It is designed for the potential treatment of neurodegenerative diseases, particularly Alzheimer's disease (AD) and other dementias. Unlike typical antagonists, iluzanebart functions as an agonist, meaning it activates the TREM2 pathway. By binding to TREM2, it mimics or enhances the action of its natural ligands, leading to the dimerization and activation of the receptor. This activation initiates intracellular signaling cascades that improve microglial survival, enhance phagocytic function, and promote a neuroprotective phenotype, thereby aiming to counteract the dysfunctional microglial state observed in neurodegenerative conditions.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.